{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-024348","form_type":"8-K/A","ticker":"BCPC","cik":"0000009326","company_name":"BALCHEM CORP","filed_at":"2022-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.692323+00:00","generated_at":"2026-06-23T16:08:03.898504+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Balchem files Kappa bioscience financials: 2021 revenue NOK 241M, net profit NOK 14.6M","bullets":["Kappa (Kechu Bidco) 2021: revenue NOK 240.9M, op. profit NOK 42.7M, net profit NOK 14.6M including NOK 26.7M discontinued ops loss.","Total assets NOK 1,059M, equity NOK 594M, borrowings NOK 245M, cash NOK 100M as of Dec 31, 2021.","Unaudited pro forma combined financials for FY2021 and H1 2022 also filed, reflecting acquisition.","Audit opinion qualified for omission of comparative info; prepared per IFRS for SEC Rule 3-05.","Discontinued ops loss of NOK 26.7M from Kappa Ingredients GmbH (deconsolidated Nov 2021)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-024348","json":"https://secwatch.observer/filing/0001628280-22-024348.json","markdown":"https://secwatch.observer/filing/0001628280-22-024348.md","text":"https://secwatch.observer/filing/0001628280-22-024348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/9326/000162828022024348/0001628280-22-024348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/9326/000162828022024348/bcpc-20220621.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T16:08:03.898504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}